Another officer bought yesterday...10,000 shares of DSCO.
This info on another biotech that I have a position...(CYPB)
Citi Maintains 'Buy' on Cypress Bioscience (CYPB), Comments on Upcoming October PDUFA for Milnacipran
10:01 AM EDT October 2, 2008
Citi maintains a 'Buy' on Cypress Bioscience Inc (Nasdaq: CYPB). Price target $22.
Citi analyst says, "We see the probability-adjusted risk/reward profile of the stock as favorable in front of the upcoming October PDUFA for milnacipran for the treatment of fibromyalgia. We forecast higher event price volatility and a 50% probability of approval based on our analysis of important key issues...2 PDUFA Scenario Outcome " We foresee two scenarios: (1) On-time approval, with immediate price appreciation to $14, and (2) delay up to 1 year due to additional data submission, with immediate price depreciation to $5.50. We do not view a delay in approval as a significant setback since both BP and the 3rd Ph 3 data, which will support the existing application, should be available by YE."
Cypress Bioscience, Inc. is developing milnacipran for fibromyalgia (FM). In March 2008, the Company completed the acquisition of Proprius Pharmaceuticals, Inc. (Proprius), to include providing personalized medicine laboratory services to rheumatologists |
